How can risk of Antibody-Dependent Enhancement (ADE) of SARS-CoV-2 be mitigated during vaccine development?
More than 90% effective: will Pfizer’s vaccine be released by the end of the year?
Extra Caution for safety and efficacy evaluation of COVID-19 vaccines
ACROBiosystems and the Fight Against COVID-19
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a series of homogeneous CD3 proteins with good bioactivity. They are verified as 1:1 heterodimers by nonreductive electrophoresis and MALS as well.
This web search service is supported by Google Inc.